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Abstract
Leishmaniasis is a group of diseases with a large spectrum, cosmopoli-
tan, but with broad and significant impact in the tropical zone. Leish-
maniasis presents itself in two forms, one visceral involving hemolinfo-
poietic system structures, other with skin and/or mucosa involvement, 
often without visceralizing. The latter, known as American Cutaneous 
Leishmaniasis (ACL) is the aim of this study. One of the major problems 
in the ACL is treatment procedure using injectable formulations, with 
risk for complications from the injection and the risk of damage to 
the liver and kidney function and cardiac complications. Several tests 
have demonstrated satisfactory results using Fluconazole®. In order to 
consolidate the results described in the literature, this study sought to 
demonstrate the therapeutic efficacy of Fluconazole® with high-dose 
treatment of ACL in patients from an endemic area in the Southern 
State of Ceará, Brazil, City of Barbalha. It’s conducted a prospective 
randomized study with two groups of patients. Sixty of the Group 
I: they were treated with 300mg or 450mg of Fluconazole® for six 
weeks. Sixty Group II: they were treated with Glucantime 20mg/kg/
day for 20 consecutive days. The diagnosis of ACL was performed with 
Imprint, culture, biopsy and histopathological stain with Giemsa and 
immunohistochemistry. Montenegro’s Intradermoreaction was also 
performed. All patients were evaluated clinically and followed up for 
ninety days. Continuous variables were evaluated by Student's t test, 
and for the correlation of variables the Pearson correlation coefficient 
(r) was used. The time healing of each group had its evaluation by 
Kaplan-Meier method. In all tests the hypothesis α was considered 
significant when less than 5% (p <0.05). The therapeutic efficacy (TE) 
was calculated based on the reduction of relative risk. The study po-
pulation was predominantly made up of individuals between 30 and 
40 years, brown skin color, peasants, rural people, with a slight pre-
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Introduction
The American tegumentary leishmaniasis (ATL) 
is an infectious disease of the skin and mucosa, 
whose etiological agent is a protozoan of the gen-
der Leishmania sp. The treatment is a challenge, 
because the drugs available on the market show, 
in general, high toxicity. Thus, therapeutic flaw, 
relapses and the resistance to the treatment mo-
tivates the search for a drug of easier use. (Lima 
et al., 2007).
The diagnosis of ATL presents a spectrum which 
permeates epidemiologic, clinic and laboratory ele-
ments. In general, there is the necessity of utilizing 
more than one among the criteria in order to achie-
ve the diagnosis of certainty. (Gontijo; Carvalho, 
2003; Manson-Bahr, 1987). 
Definitive diagnosis involves the demonstration 
of the parasite, obtained by various parasitological 
techniques of direct and indirect research. The sim-
plest technique is the direct detection of parasites 
in material obtained by scarification, aspiration or 
biopsy of the edge of the lesion, using Romanows-
ky colorings (Furtado, 1994). The polymerase chain 
reaction (PCR) is a method endowed with high 
sensitivity, capable of detecting trace quantities as 
small as a fentogram from the DNA of a leishma-
nia, equivalent to 1/10 of the parasite (Brujin; Bar-
ker, 1992), Brazil has a sensitivity of 98.41% and 
specificity of 95.59% (Gontijo, 1997). The Mon-
tenegro intradermoreaction (MIDR), as professed 
by Montenegro in 1926, prepared based on pro-
mastigotes of Leishmania cultivated, is still widely 
used and useful (José et al., 2001). The MIDR de-
tects the presence of delayed-type hypersensitivi-
ty, since, from the immunological point of view, 
LT is characterized by a cellular response during 
and after the cure of the infection, either sponta-
neously or after treatment (Carvalho et al., 1995). 
The MIDR presents positivity of 84% and 100%, 
estimated, in the cutaneous and mucocutaneous 
forms, respectively, and negative in the diffuse 
cutaneous form (SHAW; Lainson, 1975). Indirect 
immunofluorescence assay (IIFA) is the most widely 
used serological method (Marzochi et al., 1980). 
Demonstrates sensitivity greater than 60% in cu-
taneous forms, 100% in the LCM and negative in 
the LCD (KAR, 1995; Mendonca et al., 1988).
Emerged in France in the midst of World War 
II, the antimoniate of N-methyl glucamine, mar-
keted as Glucantime® (Rhône-Poulenc-Rohrer) is 
marketed in the countries of French and Spanish 
languages, as well as in Brazil, being the drug of 
first choice (RATH et al., 2003). The most common 
side effects are arthralgia, myalgia, loss of appeti-
te, headache, fever, vomiting, dizziness and swelling 
at the injection surroudings (Carvalho; Dolci, 2006). 
Are described in the literature complications such 
as cardiotoxicity, nephrotoxicity and hepatotoxicity 
of antimony, composing important limitation to the 
safe use (Carvalho, 2007). Because they are abor-
tifacient, antimony should not be administered to 
pregnant women (Gontijo; Carvalho, 2003), and 
one should use amphotericin B. Notwithstanding 
the success of antimony, the fear of the emergence 
of resistance is a fact, considering the irregular use 
in some regions (Haldar; Sen; Roy, 2011). Several 
therapeutic alternatives are recommended, especia-
lly the pentamidines.
valence of females. The results showed therapeutic efficacy of 38.7%. 
The cure was related to the size of the lesion, relevant factor in the 
statistical p <0.0001. The lesions smaller than 30 mm (alone or sum 
of multiple lesions) responded promptly to Fluconazole®.
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In the 1960s, 1970s and 1980s, drugs such as 
metronidazole, antituberculosis drugs (rifampicin 
and isoniazid), cycloguanil pamoate, nitrofurans 
(nifurtimox), trimethoprim-sulfamethoxazole and 
dapsone were tested in the treatment of leishma-
niasis, with varying efficiencies, not being possible 
to recommend them for routine therapy on the ba-
sis of unreliable data (Berman, 2005). Alternative 
treatments are used with itraconazole, ketocona-
zole, and more recently, azithromycin. Despite the 
promising results of some of these drugs, studies 
used small numbers of patients; were published as 
case reports or unsuitable study design (Blum et 
al., 2004; Ouellette et al., 2004; Silva-Vergara et al., 
2004; Zerpa et al., 2006).
Leishmania, like some fungi, use common me-
tabolic pathways, such as the synthesis of sterols. 
Thus, the growth of these organisms becomes sus-
ceptible to the sterol synthesis inhibitor (Roberts 
et al., 2003). The Fluconazol® a fungistatic, inhibi-
ting the synthesis of ergosterol (Nobre et al, 2002), 
shown promising drug in the treatment of some 
species of leishmania, the etiological agents of skin 
disease (Alrajhi et al, 2002; Hart et al., 1989). In 
vitro studies demonstrate Fluconazol® a significant 
inhibitory effect on promastigotes of Leishmania 
donovani, in some subspecies of Leishmania bra-
ziliensis and a slight or no effect on Leishmania 
aethopica, Leishmania major, Leishmania tropica 
and Leishmania mexicana (Beach; Goad; Holz, 
1988). Testings in the New-World are observed in 
the literature (Monte Neto, 2006; SOUSA et al, 
2011.)
The healing criterion is clinical. It is recommended 
monthly monitoring for three consecutive months 
and, after clinical cure, follow-up 12 months after 
treatment completion.
This paper aims to evaluate the therapeutic 
efficacy of Fluconazol® in patients with American 
Tegumentary Leishmaniasis, study its therapeutic 
activity, to compare the efficacy and the healing 
time of the treatment with Fluconazol® over the 
standard drug (Glucantime®) and evaluate Fluco-
nazol® associated side effects.
Materials and methods
This is a prospective, randomized study to evaluate 
the therapeutic efficacy of Fluconazol®, orally, in 
high doses, in patients with cutaneous leishmaniasis 
determined by Leishmania (V.) braziliensis. The study 
presented technical rigor, followed all the rules of 
biosafety related to work in humans, and the disea-
se on screen. The work considered all ethical gui-
delines for research in anima nobili following a re-
commendation from National Health Council (CNS) 
Resolution 466/12, including protecting names and 
personal data of individuals in the research. Patients 
were informed about the study and received expla-
nations about the main objective of the work, the 
procedures they underwent and the guarantee of 
confidentiality of your information and exams. Tho-
se who agreed to participate voluntarily signed the 
Informed Consent Form (ICF), developed specifically 
for this research (Brazil, 1996). 
The original project was submitted and approved 
(Protocol 4/2008) to the Ethics Committee of Hos-
pital São José of Infectious Diseases - HSJ/Health 
Secretary of the State of Ceará and appreciated by 
the Ethics Committee of the Medical Program of 
Research in Barbalha, the Federal University of Cea-
rá (UFC). It had its start in July 2009 and ending in 
December 2011.
Characterization of research subjects
Patients proceeded from Tropical Pathology Clinic 
of the Medical School of the Federal University of 
Ceará, in Barbalha. The Clinic is part of the health 
structure of the Department of Health of Barbalha, 
South Municipality of Ceará, located in the metro-
politan region of Cariri, on the banks of Araripe, at 
414 meters above sea level and 610 km far from 
Fortaleza, the capital the state. The administrative 
and technical guardianships are borne by the UFC 
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Medical School in Barbalha, home of the Clinic. The 
patients followed the criteria described in the fo-
llowing: (a) Inclusion criteria - men or women aged 
above 18 years, presenting lesion with parasitologi-
cal confirmation for leishmaniasis and without prior 
treatment to agree to participate in the study by 
signing the Instrument of Consent; (b) Exclusion cri-
teria - men or women under 18, pregnant or breast-
feeding, patients with heart disease, liver disease 
(or only increases in enzymes, SGOT, SGPT), kidney 
disease, HIV carriers; and patients who had already 
developed a mucosal form of LTA and did not agree 
to participate.
Parasitological diagnosis
After aseptic skin with iodine alcohol (commercial, 
"Deshydrater" brand) and local anesthesia with 1% 
lidocaine (commercial, Xylestesin® brand, Cristália 
laboratory) were performed biopsies (three frag-
ments) with punch of 02 mm at the edge of the 
lesion,  in place without apparent secondary infec-
tion. A fragment of 02 mm was grown in NNN 
culture medium, prepared according to standard 
technique that has been modified (Pessoa; Martins, 
1978); the other was used for imprints and the third 
set at 10% buffered formalin, for histopathological 
examination, according to standard technique (Mi-
chalany, 1998; Tolosa et al, 2003) and for immuno-
histochemical study.
The obtained smears were stained with Giemsa 
according to standard techniques (Michalany, 1998) 
and examined for Leishmania amastigotes. For the 
cultures, the collected material was inoculated into 
NNN medium containing Schneider, supplemented 
with 20% fetal bovine serum, 2% sterile human 
urine, and 100 μg gentamicin/ml. The cultures were 
incubated at 26°C for four weeks in BOD (brand 
Quimis - Q315M) and examined weekly, investiga-
ting the presence of Leishmania promastigotes.
The material, fixed in buffered formalin, was pro-
cessed, three histologic sections being made, one 
stained with haematoxylin and eosin, according 
to standard techniques (Michaelany, 1998; Tolosa 
et al., 2003); the second section was stained with 
Giemsa according to standard techniques (Tolosa et 
al., 2003) and the third section subjected to immu-
nohistochemistry.
The evaluation for immunohistochemical iden-
tification of Leishmania in tissues was performed 
on four-micrometer sections mounted on silanized 
slides (Dako - silanized slides number S3003), depa-
raffinized in xylene and ethanol, followed by hydra-
tion. Endogenous peroxidase activity was blocked 
with pig serum, followed by antigen retrieval in a 
water bath at 96°C with citrate buffer (Dako, anti-
gen retrieval solution); following, there was inhibi-
tion of specific binding with skim milk (30 ml TRIS 
+ NaCl + 0.3 g bovine albumin 0.3 g of Merck + 
skimmed milk powder). This was followed by in-
cubation with primary anti-leishmanial antibodies 
(produced in Evander Chagas Institute on the ba-
sis of Leishmania chagasi - MHOM/BR/1974/PP75), 
polyclonal antibodies at a dilution of 1/4000 with a 
reducing non-specific binding of (Dako Unspecific 
Bond Reducer) in a humid chamber for 30 minutes. 
In the following, we used biotinylated secondary 
antibody (DAKO LSAB kit). For the revelation of the 
primary antibody was used as chromogen diamin-
obenzidine, and contrasted with Harris hematoxylin 
(Duarte; Rochael, 2006).
Definition of groups and treatments
The study was randomized, containing two treatment 
groups, consisting of 60 patients each group. The 
calculation of the sample (n) was based on the Cen-
tral Limit Theorem, which advocates samples from 
more than 30 observations for continuous variables; 
the distribution of mean is Gaussian - normal (Jekel; 
Katz; Elmore, 2005).
Was performed exchanged randomization in 
blocks. In a box, were deposited 20 records; each 
half of the records had different color. The blue 
color was defined as Group I and the red as Group 
II. Each patient who met the inclusion criteria with-
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drew, randomly, a record to define in which group 
it would be included.
Group I - patients were treated with Fluconazol® 
(PRATI-Donaduzzi Laboratory - national drug indus-
try, in the state of Paraná); boxes with 100 hard 
gelatin capsules provided by the Health Department 
of the Municipality of Barbalha at a dose of 300 
or 450 mg/day. 300 mg were administered to pa-
tients weighing less than or equal to 50 kg and 
450 mg for patients weighing more than 50 kg. 
Patients received capsules of 126 or 168 Flucona-
zol® at a concentration of 150 mg/capsule, respec-
tively, havng to eat two or three capsules at once 
in the morning. The number of capsules provided 
was sufficient quantity for a six-week treatment (42 
consecutive days).
Group II - patients were treated with Glucan-
time® (provided by the Department of Health of 
Barbalha) at a dose of 20mg/kg/day. Treatment was 
carried out for 20 consecutive days intravenously 
over 30 minutes of application. The drug was dilu-
ted in normal saline serum, 250 ml, in an outpatient 
setting. Patients received ampoules corresponding 
to 20 days of treatment.
Monitoring and laboratory tests
Returns were performed after 20, 40, 60 and 90 
days. Before treatment the patients underwent a 
complete physical examination. Then, blood was co-
llected by venipuncture into BD Vacutainer ™ tubes 
of type (purple cap) for CBC; BD Vacutainer® type 
tubes (red and gray cover) for liver function tests 
(AST and ALT), renal function (urea and creatinine) 
and dosage of glucose. Followed the establishment 
of the Montenegro test, reagent obtained from 
PRCI (Production and Research Center of Immuno-
biology - Secretary of the State of Paraná Health); 
one ml bottles with Leishmania (L) amazonensis at 
a concentration of 40mg/ml of protein nitrogen. 
0.1 ml was applied, with intradermal sterile hypo-
dermic syringe on the anterior surface of the right 
forearm after sterilization with 70% alcohol. Once 
proceeded the review after 72 hours, reading was 
performed with metal calipers Azehheb brand. Fi-
nally, an ECG was performed by registering all the 
derivations.
During treatment, were carried out in two stages 
(in the middle and end of treatment), ALT dosages, 
AST, urea and creatinine (all with enzymatic kits 
LABTEST - Brazil) and an ECG for every return to 
the user of Glucantime® throughout treatment with 
antimony and urine analysis with standard analysis. 
The observed side effects were recorded at each 
visit. The blood counts were performed by an auto-
mated cytometer ABX Pentra 60, with internal and 
external quality control. The tests in biochemistry 
were performed by automated spectrophotometer 
LabMax - 240 LABTEST with control external and 
internal quality.
Patients were evaluated by the principal resear-
cher for the clinical follow-up, using the protocol 
itself and by a blinded observer (clinical doctor's 
clinic), which recorded the clinical outcome and side 
effects in the conventional patient record. The num-
ber and appearance of the lesions were described 
by both. The size (measured with calipers in milli-
meters) and location (Head, Upper Limps, Lower 
Limbs, Body Joint or Miscellaneous) were recorded. 
A photographic record of the evolution of the le-
sions, with a digital camera (12 megapixels), was 
made. Lesions with secondary infections were trea-
ted with topical antibiotics or, when necessary, a 
systemic antibiotic (azithromycin). The patients were 
examined until the full lesion(s) healing(s), with no 
evidence of inflammatory activity, which is the cure 
criteria (Brazil, 2007).
Statistic analyzes
To mount the database, was used a licensed Excel 
Microsoft Corporation 2010 © spreadsheet. Statisti-
cal analyzes were carried out using SPSS© software, 
version 17.0, licensed. The program GraphPad Prism 
©, version 3.0, licensed, was used for making gra-
phs and calculations. The estimate of treatment effi-
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cacy was obtained through the relative risk reduc-
tion of calculation. The Student Test t was used to 
compare, in both groups, the means of continuous 
variables. The level of correlation parametric data 
was evaluated by Pearson's correlation coefficient 
(r). The healing time of each group had its evalua-
tion by the Kaplan-Meier method. In all hypothesis 
tests, the α was considered significant when less 
than 5% (p <0.05).
Results
We included 120 patients with cutaneous Leishma-
niasis, selected from the eligibility criteria, a total 
of 280 patients examined at the Tropical Diseases 
Clinic of UFCA and whose etiologic agent was Leis-
hmania (V.) braziliensis (Figure 1). 
The diagnosis was confirmed by identification 
of the parasite in at least one of three parasito-
logical methods used and the Montenegro intra-
dermalreaction.  Sixty patients were primary use of 
Fluconazol® and 60 primary use of Glucantime®, 
according to inclusion criteria previously described 
(Table 1). 
The patients studied were born in the city of Bar-
balha, resident since birth, with no travel record; 
predominantly in the countryside, in both groups 
(Table 2). Most of the women were in the group 
Fluconazol® n = 34 (56.7%), and in equal numbers 
in the study group who used the Glucantime n = 30 
Figure 1:  Leishmanias observed by Immunohistochemistry (A), Histopathology - Giemsa (B) and Imprint (C) 
in material from patients with LT. Source: research data.
Table 1.  Diagnostic methods of American Tegumentary Leishmaniasis, and its expression, positive or ne-
gative.
Method
Fluconazol Glucantime
Positive
 (n) (%)
Negative  
(n) (%)
Positive
(n) (%)
Negative 
(n) (%)
Histopathological 38 (63.7%) 22 (37.5%) 31 (51.6%) 29 (48.4%)
Giemsa  28 (46.6%) 10 (16.6%) 25 (51.6%)  06 (10.0%) 
Serious threat 10 (16.6%) 28 (46.6%) 06 (10.0%) 25 (51.6%)
Imprint 58 (96.7%) 02 (03,3%) 59 (98.3%) 01 (01,7%)
Culture 38 (63.7%) 22 (37.5%) 41 (68.3%) 19 (31.7%)
Montenegro 1.61 (1.09–2.37) 0.016 2.99 (1.50–5.96) 0.002
Source: research data.
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Table 2.  Epidemiological variables and their distribu-
tions in patients with American Tegumen-
tary Leishmaniasis by treatment.
Variable
Drugs
Fluconazol n (60) Glucantime n (60)
Sexo
Woman 34 (56.7%) 30 (50.0%)
Man 26 (43.3%) 30 (50.0%)
Moradia
Rural 57 (95.0%) 60 (100.0%)
Urban 03 (05.0%) -
Ocupação
Farmer 
man 20 (33.5%) 22 (36.6%)
woman 08 (13.3%) 02 (03.3%)
Student
woman 08 (13.3%) 07 (11.6%)
man 03 (05.0%) 05 (08.3%)
Other
woman 19 (31.6%) 21 (35.0%)
man 02 (03.3%) 03 (05.0%)
Location
Lower limb 21 (35.0%) 19 (31.7%)
Top member 21 (35.0%) 22 (36.6%)
Head 05 (08.3%) 06 (10.0%)
Joint 09 (15.0%) 06 (10.0%)
Trunk 04 (06.7%) 07 (11.7%)
Mixed 40 (66.7%) 45 (75.0%)
Race
White 15 (20.0%) 12 (20.0%)
Black 05 (08.3%) 03 (05.0%)
Age
Average 41 (68.3%) 33.7 (56.1%)
Minor 18 18
Of age 88 84
Evolution (in weeks)
Average 4.9 4.6
Less time 1.0 2.0
Greatest time 12.0 12.0
Number of lesions 
Media 1.4 1.7
Minimum 1.0 1.0
Maximum 4.0 20.0
Bulbao
Present 33 (55.0%) 34 (56.7%)
Absent 27 (45.0%) 26 (43.3%)
Variable
Drugs
Fluconazol n (60) Glucantime n (60)
Weight
<50 kg 12 (20.0%) 05 (08,3%)
> 50 kg 48 (80.0%) 55 (91.7%)
Cure
Primary 40 (66.7%) 59 (98.3%)
Secondary 20 (33.7%) 01 (01,7%)
Size of injury 
(mean)
25.2 ± 18.2 27.8 ± 30.0
Source: research data.
(50.0%). This is an essentially rural population, with 
an average age between 30 and 40 years (group I, 
mean of 41 years; Group II, mean 33.7 years). The 
age difference between the two groups was evalua-
ted by the Student Test t, the result of p <0.05 was 
0.032, a result that characterizes the case of two 
distinct populations with respect to age. The stu-
died groups consisted of the resident farmers on the 
slopes of Araripe, tropical region of hot semi-arid 
type, with ombrophilous forest, home to rich fle-
botominic fauna (Silva 2004). Students, housewives 
and merchants represented the other occupation 
identified as others. Overall, sought health services, 
health care, on average, after four weeks of evo-
lution of the lesion (Group I n = 4.9 weeks; Group 
II n = 4.6 weeks). It was observed in both patient 
groups with up to three months of their skin lesion 
evolution. There were no patients who sought me-
dical care with less than a week in the populations 
studied. The minimum time was one week in Group 
I and two weeks in Group 02. All the patients of the 
search had only classical ulcerated lesions of varying 
sizes and numbers, located generally in the limbs.  
Altough the size in patients with single ulcer size 
was unitary, in patients with multiple ulcers the final 
size was configured by the size of the sum of these. 
Holders of leishmaniasis presented with complaint 
of ulcerated lesion, with or without lymphadeno-
pathy satellite. Sometimes this lymphadenopathy 
was accompanied by episodes of fever with chills, 
preceding days in ulceration (Table 2). The number 
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of ulcers in both populations, ranged from one to 
20. In Group I, the average damage was around 
1.4 in Group II around 1.7. The size of the lesions 
as measured in mm ranged from a minimum of 8.2 
mm and a maximum of 113.5 mm in Group I; in 
Group II, the minimum size was 8.0 mm and the 
maximum of 190,6mm. 
After a physical examination and laboratory tests, 
there was a weak association with comorbidities, 
especially hypertension, observed in 12 patients, 07 
treated with Fluconazol® (Table 3). There were no 
significant laboratory abnormalities of clinical interest.
In Table 4, we observe the therapeutic effects 
of drugs used in the study, which allow measuring 
the effect of these intragroup and intergroup. Inter-
group effect’s measure refers to the relative risk’s 
reduction, also known as therapeutic efficiency (TE). 
This measurement is calculated considering the 
risk of either drug alone, subsequently applying the 
formula of Coutinho; Cunha (2005). It has thus the 
following result: F.T.S. = 40/60 = 0.6; G.T.S. = 59/60 
= 0.98. The chance of healing intragroup injury, 
using the Fluconazol®, is 60%. The Glucantime® 
is 98%; however therapeutic efficacy compared to 
Fluconazol® Glucantime® would be 38.7%. Despi-
te the low therapeutic effectiveness has not been 
observed any side effects during treatment with 
Fluconazol®.
FTE = (1 – (F.T.S./G.T.S.))x100
FTE =  Fluconazol® Therapeutic Eficacy.
F.T.S. =  Fluconazol® Therapeutic Sucess,  
(Intragroup eficacy).
G.T.S. =  Glucantime® Therapeutic Sucess, 
(Intragroup eficacy)
The obtained data show that all successful results 
observed with Group I (treated with Fluconazol®), 
were found in lesions ≤ 30 mm (Table 5). The re-
lation between lesion size and the chance of cure 
by Fluconazol® exists and has proportional inverse 
correlation, as is shown by the Pearson Correlation 
Coefficient, equal to -0.7842 (negative and mode-
rate correlation, p <0.0001).
Table 3.  Clinical data of patients with American Te-
gumentary Leishmaniasis treated with Flu-
conazol® and Glucantime®.
Clinical 
aspects
Patients treated 
Totalwith 
Fluconazol
with 
Glucantime
Hypertension 07 05 12
Diabates 
mellitus
01 00 01
Mental 
retardation
01 00 01
Aortic insuf. 01 00 01
Hearing 
deficence
00 01 01
No clinic 
changes
50 54 104
Total 60 60 120
Source: research data.
Table 4.  Therapy Success intra-group of patients 
with MCL treated with Fluconazol® and 
Glucantime®.
Treatment
Patients treated 
TotalSuccess n 
(%)
Dud n 
(%)
Fluconazol 40 (66.6%) 20 60
Glucantime 59 (98.3%) 01 60
Total 99 21 120
Source: research data.
Table 5.  List of lesion size and the effect of treatment 
with Fluconazol® in patients with.
Lesion size
Effect of fluconazol
Total
Sucess Failure
>30 mm 00 20 20
≤30 mm 40 00 40
Total 40 20 60
Source: research data.
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The healing of the lesions occurred in all cases 
and in both groups. The cure criterion was es-
sentially clinical, defined by re-epithelialization of 
ulcerated lesions, total regression of the infiltration 
and erythema, up to three months after comple-
tion of the treatment regimen; criterion assessed 
by the investigator and, independently, by a blin-
ded observer as described in the methodology. 
The average healing time of Group I (Fluconazol®) 
was 45.7 days, with a minimum time of 32 days, 
occurred in two cases of young women, with 09 
mm lesion each; maximum time of 62 days ob-
served in lesions greater than 20 to 30 mm size, 
resistance to Fluconazol® and responsives to the 
20 days treatment with Glucantime®. The healing 
of the lesions in Group II (Glucantime®) occurred 
in the first 20 days of clinical follow-up in 59 pa-
tients, responsive to Glucantime®. One case of 
tegumentary leishmaniasis in a young man of 20 
lesions did not respond to conventional treatment, 
responding promptly to amphotericin B in 20 days, 
with a final cure after 40 days of clinical follow-up 
without recurrence.
Discussion 
This randomized study, performed in a population 
of 120 patients, to evaluate the therapeutic effica-
cy of Fluconazol® in high doses in the treatment 
of tegumentary leishmaniasis was justified and is 
justified in light of the risks related to the use of 
first-line drugs, in general, in elderly patients, es-
pecially in cardiac, hepatopathic and nephropathic 
patients, to the exclusive use of these injectable, 
to complications at the application site, among 
other discomforts and contraindications. Follows 
the line of several studies conducted in endemic 
areas, including the Baturité region in order to find 
an alternative drug for the treatment of American 
tegumentary leishmaniasis by Leishmania (V.) bra-
ziliensis (Laffitte; Gentonb; Panizzon, 2005; Alrajhi 
et al., 2002.) The target population of this study 
was represented by patients in general the coun-
tryside, in the Municipality of Barbalha, randomly 
divided into two groups - Group I, with 60 patients 
using Fluconazol®, 300 or 450mg/day. 300 mg 
have been administered to patients weighing less 
than or equal to 50 kg, and 450 mg for patients 
weighing more than 50 kg. A Group II represen-
ted by patients using Glucantime® 20mg/kg/day 
treated for 20 days intravenously over 30 minutes 
of application.
The study subjects were represented, mostly by 
rural workers people in the city of Barbalha, not 
floating fixed residents, study site, residents on 
the slopes of Araripe, forest zone to the south of 
Ceará. This fact shows that the American tegu-
mentary leishmaniasis in Barbalha is still zoonosis, 
as described in the literature (Brazil, 2015; Gontijo; 
Carvalho, 2003). The subjects, mostly, are mesti-
zos (mixed skin color), slightly higher prevalence 
in females in the group Fluconazol® 34F (56.6%), 
26H (43.7%). The GROUP II population was equi-
valent in gender, 50% of men and 50% women. 
Apparently, in Barbalha, women, like men, attend 
the woods. The literature shows that leishmaniasis 
is predominant in males (Travi et al., 2002). The 
studied population of young adults, with a mean 
age of 41 years (68.3%) in Group I and age of 
33.7 years (56.1%) in Group II. The national lite-
rature states that ATL occurs in both sexes and 
all age groups, however, in the country's average, 
predominantly greater than ten years, in 90% of 
cases in males, with 74% of the sample (Brazil, 
2015). The average disease duration in Group I 
was 4.9 weeks (± 2.2 standard deviation), a little 
over a month; Group II was 4.6 weeks (± 2.2 stan-
dard deviation), very close to Group I. The studies 
show that for LCM means dertermined by L. (V.) 
panamensis, in Colombia, the evolution period is 
situated around two to three months (Osorio; Cas-
tillo; Ochoa, 1998). This fact seems to show that 
inhabitants of Barbalha area who care about the 
health or immunobiology of local leishmaniasis 
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must have a different profile. A data of interest 
found was that slightly more than 50% of MCL 
cases studied are presented in the form bubo-
nic (Group I: 33(55.0%) and Group II 34(56.7%)). 
This form of leishmaniasis, determined by L (V.) 
braziliensis, is described in the literature (Sousa et 
al., 1995). Manifested with satellite lymphadeno-
pathy at important times, with or without fever 
and chills. The status preceeds days or weeks to 
the onset of ulceration and lymph node puncture 
shows plenty of amastigotes (Bomfim, et al., 2007, 
Sousa et al., 1995).
Regarding comorbidities, we found a low asso-
ciation with the LTA other synchronous disease. 12 
patients had hypertension, controlled in treatment, 
one diabetic, one oligophrenic accompanied by the 
local CAPS, one with hearing loss and  one with 
aortic insufficiency. Comorbidities did not influence 
the course of the disease, nor interfere with the 
suggested treatment. There are descriptions, in-
creasingly growing in the ATL association with HIV-
positive patients, not shown in this study (Rabello; 
Orsini; Disch; 2003).
In the diagnosis of ACL, the methodologies 
showed variable sensitivity. The Imprint as para-
sitological examination revealed important sensi-
tivity in both studied groups (Group I: 58 (96.7%), 
59 (98.3%)). Studies show the sensitivity of the 
method, easy, low cost and high sensitivity when 
performed with good technique and by experti-
se (Light et al. 2009; Bahamdan, 1996). The fin-
dings corroborate the literature (Gontijo; Carval-
ho, 2003). Montenegro, like Imprint, showed high 
sensitivity in both groups (Group I: 56(93.3%), 
Group II: 55(91.6%)). Montenegro should not be 
used in isolation when the investigation of pa-
tients in endemic areas, considering the high level 
of awareness of individuals in these regions (Per-
son; Lopes, 1963; Marzochi, 1992). The biopsy 
with histopathological is not a sensitive method 
for diagnosing ATL, especially in mucocutaneous 
form (Ridley; Magalhães; Marsden, 1989) and 
should be used in the differential diagnosis of skin 
deep mycoses (chromomycosis, blastomycosis) and 
skin cancer, basal cell ulcerated and epidermoid 
(Magalhães; Chiarini; Raick, 1982). The findings 
of this trial confirm the literature data (Group I: 
38 (63.7%), Group II: 31 (51.6%)). The culture of 
Leishmania from skin punch is important parasito-
logical method with high sensitivity, but this study 
showed equivalence with histopathology, accor-
ding to various contamination during the proce-
dure (Group I: 38 (63.7%), Group II : 41 (68.3%)). 
It is an effective method, but with long-term and 
need for refinement in the collection, as well as 
during incubation time and growth monitoring of 
parasites (Rodrigues, 2000).
Perhaps one of the major problems, in the me-
dical context, of tegumentary leishmaniasis is in 
the treatment (Reithinge et al., 2007). It is the 
penury to the sick with its wound(s) open, of-
ten deforming for leaving scar(s). Even that took 
place several decades of his advent by Gaspar 
de Oliveira Viana, pentavalent antimony, trivalent 
originally known as tartar emetic (TE), did not find 
suitable replacements (Costa, 1992; Mitropoulos; 
Konidas, Durkin-Konidas, 2010). Leishmaniasis is 
as old as human history, as civilization (Piscopo; 
Mallia, 2006). Since ancient times, there are re-
ports of tegumentary leishmaniasis, existing des-
criptions of its clinical manifestations in the library 
of King Assurbanipal in the 7th century BC (Man-
son-Bahr, 1996). Initially, patients were treated 
with TL with local ointments and plant extracts. 
Only in the nineteenth century, in Tashkent, capi-
tal of Uzbekistan, the main city in Central Asia, in 
the foothills of the mountains with rich Golestan 
flebotômica fauna, we started to use pure lactic 
acid as abrasive injuries. Several other abrasives 
were used during this period with relative success 
or uncertain (Berman, 1988).
It fell to Oliveira Viana Gaspar use, for the first 
time, the trivalent antimony, known at the time as 
tartar emetic (Demicheli; Frézard, 2005). The tri-
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valent antimony was already used as an emetic in 
the treatment of syphilis and even arthritis (Wel-
don et al., 1983). Side effects, such as depression, 
coughing and chest pain, were identified as nega-
tives, investing in the alternative treatment demand 
(BERMAN, 1988). These undesirable effects of TE 
instigated the research, culminating in the develop-
ment of pentavalent antimony (SbV), as estibamina 
urea, estibosan and neoestibosan in 1920 (Almeida, 
Santos et al. 2011).
Treatment of tegumentary leishmaniasis, in sim-
ple ulcerated form, is recommended to accelerate 
the healing process and prevent the continuation 
or dissemination of the parasite, and minimize 
scarring deformations (Blum et al., 2004, Weina et 
al., 2004). Unlikely in the LCM and in the kalazar, 
treatment should always be performed, because 
these forms of leishmaniasis can complicate and 
culminate in death (Brazil, 2006; Davidson, 1998). 
In regions where leishmaniasis is endemic, there 
is the provision, by the official health agencies, 
for free treatment of all patients, although there 
are failures, sometimes important, in consequen-
ce to this demand, because of the quantitative 
limitation of the therapeutic arsenal and the lack 
of qualified professionals for diagnosis and moni-
toring treatment (Reithinger et al., 2007).
The control of tegumentary leishmaniasis 
nowadays is only based on pharmacotherapy, sin-
ce the vaccines did not show the desired effect, 
but there are several ongoing trials to develop a 
vaccine with high prophylactic efficacy (Palatnik-
De-Sousa, 2008). The primary treatment remains 
pentavalent antimony in sodium stibogluconate 
formula (Pentostan®, Glaxo Wellcome, London, 
UK), often used in English-speaking countries or 
as N-methylglucamine antimoniate (Glucantime®, 
Rhone-Poulenc- Rohrer, Paris, France), used mainly 
in Latin America and French or Spanish-speaking 
nations (Berman, 1988; Rath et al. 2003). Compa-
rative study between the two formulations was 
conducted in Kenya, showing better economic via-
bility of Glucantime® (Moore et al., 2001). Howe-
ver, the World Health Organization (WHO) states 
that the therapeutic efficacy of Glucantime® de-
pends on several factors, such as geographic lo-
cation and the types protocols of treatments used 
(Gontijo; Carvalho, 2003). Most endemic regions, 
with the exception of Venezuela, French Guiana 
and Suriname, which have their own health poli-
cies, follow the WHO guidelines for the treatment 
of American tegumentary leishmaniasis, the use of 
20 mg/kg Glucantime® by daily for 20 consecuti-
ve days (Reithinger et al., 2007). The original gui-
dance was 10bmgSbV/kg (Glucantime®), however, 
with the emergence of non-responsive cases to 
the treatment, particularly in Indian Territory in the 
1970s, was nominated this new dosage (Thakur et 
al., 1999) Evidences describe that TL response to 
treatment depends on the species and strain of 
Leishmania sp. (Almeida, Santos et al. 2011; Areva-
lo et al. 2007; Yardley et al. 2006). In addition, the 
use of pentavalent antimony is threatened by na-
tural development of resistance of parasites to this 
drug (Croft; Sundar; Fairlamb, 2006). These events 
triggered, in recent years, the search options for 
chemotherapy of leishmaniasis, based on drugs 
used in similar diseases, biotechnological potential 
isolated substances of plants and micro-organism, 
as well as substances used in popular medicine 
(Lima et al., 2007).
The literature describes approximately 25 com-
pounds with antileishmanial properties, although 
only a few are used in the treatment of leishma-
niasis. In general, they present one or more disad-
vantages such as high production cost, difficulty 
of administration, toxicity, determine the develop-
ment of resistance (Mishra; Saxena; Singh, 2007). 
Currently, for non-responsive to the pentavalent 
cases, it is used the amphotericin B, including its 
liposomal formulation; the pentamidinas and paro-
momycin (Brazil 2007). On the other hand, major 
side effects and the high production cost limit their 
use (Mishra; Saxena; Singh, 2007). Moreover, some 
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cases have been described resistant to treatment 
with pentamidine (Basselin et al., 2002). Studies 
show four new potential drugs in the treatment 
of LV, including liposomal amphotericin B (Berman, 
1998), oral miltefosine and sitamaquine (Sundar, 
Rai, 2002; Moore and Lockwood, 2010), these two 
in test in India; and a parenteral formulation Ami-
nosidine, the Paromomycin (Thakur et al., 2000). 
With regard to tegumentary leishmaniasis, topical 
formulations of paromomycin were introduced 
(Soto et al., 2001; Santos et al., 2008); the immu-
nomodulator imiquimod (Garnier; Croft, 2002) and 
very promising use of Fluconazol® orally (Gonzalez, 
2002).
Several studies demonstrate the potential the-
rapeutic efficacy of Fluconazol® orally, for an ave-
rage of six weeks from several different species 
of Leishmania (Alrhaji et al., 2002; Sousa et al., 
2011; Laffitte; Gentonb; Panizzon, 2005; Mino-
dier et al., 2005). This study aimed to evaluate 
the therapeutic efficacy of Fluconazol® in high 
doses orally, compared to standard treatment re-
commended by the Ministry of Health of Brazil. 
Sixty patients with a minimum age of 18 years 
underwent treatment for six weeks. At the end of 
the study, 40 have been successful in treatment, 
equivalent to 66.6% (intra-effectiveness) of the 
study population, while individuals with the stan-
dard treatment, traditional treatment, obatained 
59 satisfactory results (98.3%). The calculation of 
the final ET was 38.7%. No Fluconazol® group 
patient had adverse reactions, significant changes 
in hepatic, renal or cardiac function. Assessing pa-
tients treated with Fluconazol® all failures occu-
rred in those with lesions greater than 30 mm. By 
withdrawing patients from Group I, with greater 
than 30 mm lesions, we would have a therapeu-
tic effectiveness superior to treatment performed 
with Glucantime, skirting the 100%. Reviewing 
the literature, only one paper considers the size 
of the lesions (Alrhaji et al., 2002). In this study of 
80 patients using Fluconazol®, the lesions had an 
average size of 17 ± 11 mm. In this test, the ave-
rage size of the lesions in Fluconazol® the group 
was around 25.2 mm, with a standard deviation 
of ± 28.2; Glucantime in the group with 27.8 mm 
and standard deviation of ± 30. This fact changes 
the look regarding the treatment of tegumentary 
leishmaniasis with Fluconazol® in lesions with sizes 
larger than 30 mm. The data obtained in the study 
are not the case. The relationship between lesion 
size and the chance of cure by Fluconazol® exists 
and has inverse proportional correlation, as shown 
by the Pearson correlation coefficient, equal to 
-0.7842 (negative and moderate correlation). This 
correlation is significant at p <0.05 (0.0001). The 
cause of this association is not clear in the study, 
nor this was the object of this work.
The survival curve Kaplan-Meir and the Logrank 
test show there is cure, but at different times 
present statistical significance with Glucantime® 
earlier and the Fluconazol® a little later. This di-
fference loses significance, considering that the 
average time difference is 20 days and the bene-
fits from the oral treatment overlap with the time 
difference, reducing the risks of complication. In 
the present study was not observed side effect 
with Fluconazol®. There was, however, a downside 
- the cost of treatment. A treatment of tegumen-
tary leishmaniasis with Glucantime® considering a 
young adult, using an average dose (two ampoules 
daily for 20 days), cost R$ 296.00 (two hundred 
ninety-six reais); treatment of cutaneous leishma-
niasis with Fluconazol® considering a young adult, 
using an average dose of three tablets of 150 mg 
daily for 42 days (six weeks), was R$ 1,127.30 (one 
thousand one hundred and twenty seven reais and 
thirty cents).
In conclusion it may be said that, at least in 
patients with ATL derived from Barbalha, lesions 
larger than 30 mm, and in young adults without 
comorbidities the conventional treatment with Glu-
cantime should be preferred. In other cases, asses-
sed the patient's condition, the Fluconazole would 
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be the drug of choice. This would avoid the daily 
commute of the patient, resident in farm, from 
the foot of the plateau of Araripe, to the Health 
Centre, aiming to take the injectable formulation 
of Glucantime. This would also spare the patient 
the discomfort of the injection application and its 
complications, and adverse effects on liver, kidney 
and heart functions. There would not be, in prin-
ciple, the need for control tests during treatment, 
only the initial routine to assess the real situation of 
the patient. Moreover, an Imprint, associated with 
the Montenegro, would be the preferred method 
to make the diagnosis.
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